Advanced search
Publication Cover
Expert Review of Hematology Volume 6, 2013 - Issue 6
Submit an article Journal homepage
148
Views
1
CrossRef citations to date
0
Altmetric
Reviews

The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm

Drorit G MerkelDivision of Hematology, the Chaim Sheba Medical Center, Tel-Hashomer, Tel Aviv University, IsraelCorrespondence[email protected]
&
Arnon NaglerDivision of Hematology, the Chaim Sheba Medical Center, Tel-Hashomer, Tel Aviv University, Israel
Pages 665-676 | Published online: 10 Jan 2014

References

  • Rollison De, Howlader N, Smith MT et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 112(1), 45–52 (2008).
  • Quesnel B, Guillerm G, Vereecque R et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91(8), 2985–2990 (1998).
  • Jiang Y, Dunbar A, Gondek LP et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113(6), 1315–1325 (2009).
  • Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann. Intern. Med. 134(7), 573–586 (2001).
  • Santini V. Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes. Expert Rev. Hematol. 2(2), 121–127 (2009).
  • Chuang JC, Yoo CB, Kwan JM et al. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine. Mol. Cancer Ther. 4(10), 1515–1520 (2005).
  • Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res. 66(5), 2794–2800 (2006).
  • Stresemann C, Bokelmann I, Mahlknecht U, Lyko F. Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol. Cancer Ther. 7(9), 2998–3005 (2008).
  • Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 20(10), 2429–2440 (2002).
  • Fenaux P, Mufti Gj, Hellstrom-Lindberg E et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 10(3), 223–232 (2009).
  • Lubbert M, Suciu S, Baila L et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J. Clin. Oncol. 29(15), 1987–1996 (2011).
  • Kantarjian H, Issa JP, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106(8), 1794–1803 (2006).
  • Steensma DP, Baer MR, Slack JL et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J. Clin. Oncol. 27(23), 3842–3848 (2009).
  • Kornblith AB, Herndon JE2nd, Silverman LR et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J. Clin. Oncol. 20(10), 2441–2452 (2002).
  • Kantarjian H, Oki Y, Garcia-Manero G et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109(1), 52–57 (2007).
  • Lyons RM, Cosgriff TM, Modi SS et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J. Clin. Oncol. 27(11), 1850–1856 (2009).
  • Martin MG, Walgren RA, Procknow E et al. A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes. Am. J. Hematol. 84(9), 560–564 (2009).
  • Silverman LR, Fenaux P, Mufti GJ et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 117(12), 2697–2702 (2011).
  • Nazha A, Kantarjian HM, Cortes JE et al. Outcome of patients with myelodysplastic syndrome (MDS) with bone marrow (BM) blasts between 10 to 30% treated with hypomethylating agents versus intensive chemotherapy. ASH Annu. Meeting Abstr. 120(21), 4928 (2012).
  • Pierdomenico F, Esteves S, Almeida A. Efficacy and tolerability of 5-day azacytidine dose-intensified regimen in higher-risk MDS. Ann. Hematol. 92(9), 1201–1206 (2013).
  • Iastrebner M, Jang JH, Nucifora E et al. Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience. Leuk. Lymphoma 51(12), 2250–2257 (2010).
  • Lee JH, Jang JH, Park J et al. A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome Haematologica 96(10), 1441–1447 (2011).
  • van der Helm LH, Alhan C, Wijermans PW et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. Br. J. Haematol. 155(5), 599–606 (2011).
  • Duong VH, Lancet JE, Alrawi E et al. Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models. Leuk. Res. 37(5), 510–515 (2013).
  • Fianchi L, Criscuolo M, Lunghi M et al. Outcome of therapy-related myeloid neoplasms treated with azacitidine. 5, 44 (2012)Leuk Res; 37(5):510–5 (2013).
  • Uchida T, Ogawa Y, Kobayashi Y et al. Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes. Cancer Sci. 102(9), 1681 (2011).
  • Oki Y, Kondo Y, Yamamoto K et al. Phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan. Cancer Sci. 103(10), 1839–1847 (2012).
  • Borthakur G, Ahdab SE, Ravandi F et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk. Lymphoma 49(4), 690–695 (2008).
  • Bhatnagar B, Zandberg DP, Vannorsdall EJ et al. Lack of response of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) to decitabine after failure of azacitidine. ASH Annu. Meeting Abstr. 120(21), 3858 (2012).
  • Garcia-Manero G, Gore SD, Cogle C et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J. Clin. Oncol. 29(18), 2521–2527 (2011).
  • Garcia-Manero G, Gore SD, Kambhampati S et al. Safety and efficacy of oral azacitidine (CC-486) administered in extended treatment schedules to patients with lower-risk myelodysplastic syndromes. ASH Annu. Meeting Abstr. 120(21), 424 (2012).
  • Stauder R. The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients. Ann. Hematol. 91(9), 1333–1343 (2012).
  • Seymour JF, Fenaux P, Silverman LR et al. Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. Crit. Rev. Oncol. Hematol. 76(3), 218–227 (2010).
  • Itzykson R, Thepot S, Quesnel B et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 117(2), 403–411 (2011).
  • Wijermans P, Lubbert M, Verhoef G et al. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J. Clin. Oncol. 18(5), 956–962 (2000).
  • Qin T, Castoro R, El Ahdab S et al. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS ONE 6(8), e23372 (2011).
  • Delhommeau F, Dupont S, Della Valle V et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360(22), 2289–2301 (2009).
  • Itzykson R, Kosmider O, Cluzeau T et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 25(7), 1147–1152 (2011).
  • Link PA, Baer MR, James SR, Jones DA, Karpf AR. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. Cancer Res. 68(22), 9358–9366 (2008).
  • Voso Mt, Fabiani E, Piciocchi A et al. Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine. Leukemia 25(12), 1910–1913 (2011).
  • Jabbour E, Garcia-Manero G, Ravandi F et al. Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine. Clin. Lymphoma Myeloma Leuk. 13(2), 131–138 (2013).
  • Fenaux P, Bowen D, Gattermann N et al. Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. Leuk. Res. 34(11), 1410–1416 (2010).
  • Platzbecker U, Aul C, Ehninger G, Giagounidis A. Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil. Ann. Hematol. 89(4), 427–428 (2010).
  • Santini V, Fenaux P, Mufti GJ et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur. J. Haematol. 85(2), 130–138 (2010).
  • Itzykson R, Thepot S, Beyne-Rauzy O et al. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine? Leuk. Res. 36(4), 397–400 (2012).
  • Martinez-Frances A. Adverse effects of azacitidine: onset, duration, and treatment. Adv. Ther. 28(Suppl. 4), 1–5 (2010).
  • Toma A, Fenaux P, Dreyfus F, Cordonnier C. Infections in myelodysplastic syndromes. Haematologica 97(10), 1459–1470 (2012).
  • Fenaux P, Gattermann N, Seymour JF et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br. J. Haematol. 149(2), 244–249 (2010).
  • Merkel D, Filanovsky K, Gafter-Gvili A et al. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study. Am. J. Hematol. 88(2), 130–134 (2013).
  • Greenberg PL, Garcia-Manero G, Moore M et al. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. Leuk. Lymphoma 54(2), 321–328 (2013).
  • Douvali E, Papoutselis M, Spanoudakis E et al. Safety and efficacy of azacitidine in Myelodysplastic Syndrome (MDS) patients with mild and moderate renal impairment. Presented at: ASH Annual Meeting Abstracts 120(21), 1716 (2012).
  • Batty GN, Kantarjian H, Issa JP et al. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. Clin. Lymphoma Myeloma Leuk. 10(3), 205–210 (2010).
  • Musto P, Maurillo L, Spagnoli A et al. Azacitidine for the treatment of lower risk myelodysplastic syndromes: a retrospective study of 74 patients enrolled in an Italian named patient program. Cancer 116(6), 1485–1494 (2010).
  • Fili C, Malagola M, Follo MY et al. Prospective Phase II Study on 5-days Azactidine (5d-AZA) for treatment of symptomatic and/or erythropoetin unresponsive patients with Low/INT-1 risk myelodysplastic syndromes Clin Cancer Res (2013) (Epub ahead of print).
  • Sayar H, Chan RJ, Orschell CM et al. Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the Hoosier Oncology Group. Leuk. Res. 35(8), 1108–1110 (2011).
  • Mishra A, Lancet JE, Ali NHA et al. Outcome of Patients with Lower-Risk Myelodysplastic Syndrome (MDS) After Azacitidine (AZA) Treatment Failure. Presented at: ASH Annual Meeting Abstracts 120(21), 2815 (2012).
  • Komrokji RS, Bally C, Itzykson R et al. Azacitidine Treatment for Lenalidomide (LEN)-Resistant Myelodysplastic Syndrome (MDS) with Del 5q. Presented at: ASH Annual Meeting Abstracts 120(21), 3833 (2012).
  • Jabbour E, Mathisen MS, Garcia-Manero G et al. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. Am. J. Hematol. 88(3), 198–200 (2011).
  • Platzbecker U, Schetelig J, Finke J et al. Allogeneic hematopoietic cell transplantation in patients' age 60–70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. Biol. Blood Marrow Transplant. 18(9), 1415–1421 (2012).
  • Engel NR, Rank A. Epigenomics in hematopoietic transplantation: novel treatment strategies. Epigenomics 3(5), 611–623 (2011).
  • Kim DY, Lee JH, Park YH et al. Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome. Bone Marrow Transplant. 47(3), 374–379 (2012).
  • Steensma DP. Tuning the rigging before sailing off into the stormy sea of stem cell transplants for patients with myelodysplastic syndromes. Biol. Blood Marrow Transplant. 18(8), 1145–1147(2012).
  • De Padua Silva L, De Lima M, Kantarjian H et al. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant. 43(11), 839–843 (2009).
  • Field T, Perkins J, Huang Y et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 45(2), 255–260 (2010).
  • Greenberg Pl, Attar E, Bennett JM et al. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J. Natl Compr. Canc. Netw. 9(1), 30–56 (2011).
  • Lubbert M, Bertz H, Ruter B et al. Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant. 44(9), 585–588 (2009).
  • Cogle CR, Imanirad I, Wiggins LE et al. Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes. Clin. Adv. Hematol. Oncol. 8(1), 40–46 (2010).
  • Gerds AT, Gooley TA, Estey EH, Appelbaum FR, Deeg HJ, Scott BL. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol. Blood Marrow Transplant. 18(8), 1211–1218 (2012).
  • Damaj G, Duhamel A, Robin M et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. J. Clin. Oncol. 30(36), 4533–4540 (2012).
  • Jabbour E, Giralt S, Kantarjian H et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 115(9), 1899–1905 (2009).
  • De Lima M, Giralt S, Thall PF et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 116(23), 5420–5431 (2010).
  • Bolanos-Meade J, Smith BD, Gore SD et al. 5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation. Biol. Blood Marrow Transplant. 17(5), 754–758 (2011).
  • Platzbecker U, Wermke M, Radke J et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 26(3), 381–389 (2012).
  • Czibere A, Bruns I, Kroger N et al. 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant. 45(5), 872–876 (2010).
  • Schroeder T, Czibere A, Platzbecker U et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 27(6), 1229–1235 (2013).
  • Kim SY, Cho SG, Cho BS et al. Azacytidine treatment after discontinuation of immunosuppressants in patients with myelodysplastic syndrome and relapse after allo-SCT at a single center. Bone Marrow Transplant. 45(8), 1375–1376 (2010).
  • Lal G, Zhang N, Van Der Touw W et al. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J. Immunol. 182(1), 259–273 (2009).
  • Goodyear OC, Dennis M, Jilani NY et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 119(14), 3361–3369 (2012).
  • Gore SD, Baylin S, Sugar E et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 66(12), 6361–6369 (2006).
  • Blum W, Klisovic RB, Hackanson B et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J. Clin. Oncol. 25(25), 3884–3891 (2007).
  • Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 108(10), 3271–3279 (2006).
  • Soriano AO, Yang H, Faderl S et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110 (7), 2302–2308 (2007).
  • Kuendgen A, Bug G, Ottmann OG et al. Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid. Clin. Epigenet. 2, 389–399 (2011).
  • Fandy TE, Herman JG, Kerns P et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 114(13), 2764–2773 (2009).
  • Nand S, Godwin J, Smith S et al. Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leuk. Lymphoma 49(11), 2141–2147 (2008).
  • Bayraktar UD, Domingo GC, Schmit J, Pereira D. Azacitidine combined with gemtuzumab ozogamicin in patients with relapsed/refractory acute myeloid leukemia. Leuk. Lymphoma 52(5), 913–915 (2011).
  • Sekeres MA, List AF, Cuthbertson D et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J. Clin. Oncol. 28(13), 2253–2258 (2008).
  • Sekeres MA, O'Keefe C, List AF et al. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. Am. J. Hematol. 86(1), 102–103 (2008).
  • Platzbecker U, Braulke F, Kündgen A et al.; German MDS Study Group. Seuqnetial combination of azacytidine and lenalidomide in del (5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study. Leukemia 27, 1403–1407 (2013).
  • Silverman LR. Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents. Leuk. Res. 33(Suppl. 2), S18–21 (2009).
  • Itzykson R, Fenaux P. Optimizing hypomethylating agents in myelodysplastic syndromes. Curr. Opin. Hematol. 19(2), 65–70 (2012).
  • Ornstein MC, Sekeres MA. Combination strategies in myelodysplastic syndromes. Int. J. Hematol. 95(1), 26–33 (2012).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.